Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2017-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2016年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2016 from a company. It details the attendance and activities of independent directors at board meetings and shareholders' meetings, their independent opinions on various board resolutions, and their efforts to protect investor rights. The content focuses on governance, oversight, and compliance with laws and regulations, rather than presenting financial statements or audit results. It is a report by the board members (independent directors) about their duties and activities during the year. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board activities and management oversight. The document is not an annual report, audit report, or earnings release, nor is it a proxy or voting result announcement. The length and detail also indicate it is a substantive report, not a brief announcement or certification.
2017-03-30 Chinese
非经营性资金占用及其他关联资金往来情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a special statement regarding non-operating fund occupation and other related party fund transactions for the year 2016 by 启迪古汉集团股份有限公司. It includes a summary table of these transactions and references an audit report signed on March 29, 2017, with an unqualified opinion. The document is focused on compliance with regulatory requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. It is not a full annual report or audit report but a specific disclosure related to related-party transactions and fund occupation, which is typically part of regulatory filings or special disclosures. The document length is short (1666 characters), and it does not contain full financial statements but a summary table and auditor's review statement. Therefore, it fits best under Regulatory Filings (RNS) as a special compliance disclosure rather than a full Audit Report (AR) or Annual Report (10-K).
2017-03-30 Chinese
第七届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding the approval of various reports and proposals related to the fiscal year 2016, including the Supervisory Board's work report, the full annual report and summary, the financial statements, profit distribution plan, internal control evaluation report, and asset impairment provision. The document is dated March 31, 2017, and mentions that some of these items will be submitted to the 2016 Annual General Meeting for approval. The document is relatively short (1646 characters) and primarily serves as an announcement of the Supervisory Board's meeting resolutions rather than the full annual report itself. It does not contain detailed financial statements or substantive financial data but references the reports and their approval. Therefore, it fits best as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and approvals related to the annual report and other documents, not the full annual report or financial report itself.
2017-03-30 Chinese
第七届董事会第八次会议独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion statement related to the company's board meeting, specifically the seventh board's eighth meeting. It discusses matters such as related party transactions, guarantees, profit distribution proposals, appointment of auditors, internal control evaluation, and asset impairment provisions. The content is focused on governance and oversight opinions rather than financial results or detailed financial statements. It references regulatory guidelines and audit opinions but does not contain full financial reports or earnings data. The document is not a full annual report, audit report, or earnings release. It is a governance-related document expressing independent directors' opinions on board matters and company governance issues. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short (1591 characters), and it is not merely an announcement or certification but a substantive opinion document from independent directors.
2017-03-30 Chinese
关于计提大额资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding the decision to make a large asset impairment provision. It details the background, the amount of impairment, the impact on financials, and includes opinions from the board, independent directors, audit committee, and supervisory board. The document is relatively short (1625 characters) and focuses on a specific accounting event rather than presenting full financial statements or comprehensive financial performance. It does not contain full financial data or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a certification or a regulatory compliance filing. The content is a formal announcement about a significant accounting decision affecting the financials, which fits best under Regulatory Filings (RNS) as it does not meet the criteria for a full audit report or annual/interim report, nor is it a voting result or management change announcement.
2017-03-30 Chinese
2016年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed financial statements including consolidated balance sheets, income statements, cash flow statements, and statements of changes in equity for the year ended December 31, 2016. The text includes auditor responsibilities, management responsibilities, and an auditor's opinion, which are typical components of an audit report. The document is approximately 15,000 characters long and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it is classified as an Audit Report / Information (AR). FY 2016
2017-03-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.